Eli Lilly (NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.